43 0 2


MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.

Learn more

Company Highlights

  • Emerging leader in developing therapeutics for immuno-oncology and autoimmune disorders
  • Fully-integrated mAb-based development capabilities, including proprietary technology platforms and protein engineering expertise
  • Differentiated pipeline directed against both novel and validated targets
  • Collaborations with Janssen, Takeda, Gilead, Servier, Boehringer Ingelheim and Pfizer
  • Experienced management team and highly collaborative corporate culture
Learn more


Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

Learn more

In the News

September 27, 2012 | Fierce Biotech

10 Next-gen Biologics Platforms to Watch
"First-generation biologics took a long time to reach their commercial potential, with many setbacks along the way. The test of faith among biotech companies such as Amgen, Genentech and Biogen Idec paid off with blockbuster products that brought game-changing drugs to patients and turned those once-small players into giants....

Now, second-generation platforms are looking to make the same dramatic impact on patient care as first-generation monoclonal antibodies. In some cases, companies developing these platforms are taking the risk that their products are superior to first-generation products. They believe that theirs, for instance, could be more potent against disease targets--including having the ability to treat more than one aspect of a disease simultaneously--or have other positive attributes, including better and cheaper production processes or fewer side effects....

MacroGenic's Dual-Affinity Re-Targeting (DART) technology can target multiple disease-causing cells or different disease-causing pathways with one antibody, part of the new generation of bispecific antibodies."

Link to full story

« back to news list

News Archive: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All